The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality?
Vladutiu
Georgirene D
GD
Departments of Pediatrics, Neurology and Pathology, School of Medicine & Biomedical Sciences, The State University of New York at Buffalo, Buffalo, NY 14214, USA. gdv@buffalo.edu
D054796:Drug Dosage Calculations; D004348:Drug Labeling / Q000331:legislation & jurisprudence* / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics / Q000331:legislation & jurisprudence*; D011110:Polymorphism, Genetic / Q000187:drug effects / Q000502:physiology; D012107:Research Design / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology
D014859:Warfarin